267 related articles for article (PubMed ID: 27579296)
1. Oncolytic adenovirus-mediated therapy for prostate cancer.
Sweeney K; Halldén G
Oncolytic Virother; 2016; 5():45-57. PubMed ID: 27579296
[TBL] [Abstract][Full Text] [Related]
2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
3. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-based therapy for prostate cancer.
Ekblad M; Halldén G
Curr Opin Mol Ther; 2010 Aug; 12(4):421-31. PubMed ID: 20677093
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination.
Sato-Dahlman M; LaRocca CJ; Yanagiba C; Yamamoto M
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455560
[TBL] [Abstract][Full Text] [Related]
8. Past, Current, and Future of Immunotherapies for Prostate Cancer.
Boettcher AN; Usman A; Morgans A; VanderWeele DJ; Sosman J; Wu JD
Front Oncol; 2019; 9():884. PubMed ID: 31572678
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer.
Yang K; Feng S; Luo Z
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552019
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
Duarte C; Jimeno A; Kessler ER
Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
Freytag SO; Stricker H; Pegg J; Paielli D; Pradhan DG; Peabody J; DePeralta-Venturina M; Xia X; Brown S; Lu M; Kim JH
Cancer Res; 2003 Nov; 63(21):7497-506. PubMed ID: 14612551
[TBL] [Abstract][Full Text] [Related]
13. Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses.
Green-Tripp G; Nattress C; Halldén G
Front Mol Biosci; 2022; 9():901392. PubMed ID: 35813830
[TBL] [Abstract][Full Text] [Related]
14. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
Shiota M; Eto M
Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
[TBL] [Abstract][Full Text] [Related]
15. Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer.
Tazawa H; Kuroda S; Hasei J; Kagawa S; Fujiwara T
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28698504
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.
Halldén G; Portella G
Expert Opin Ther Targets; 2012 Oct; 16(10):945-58. PubMed ID: 22880939
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.
Crona DJ; Whang YE
Cancers (Basel); 2017 Jun; 9(6):. PubMed ID: 28604629
[TBL] [Abstract][Full Text] [Related]
18. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
19. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
20. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
Ranki T; Särkioja M; Hakkarainen T; von Smitten K; Kanerva A; Hemminki A
Int J Cancer; 2007 Jul; 121(1):165-74. PubMed ID: 17315187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
